Bill Nye is back in his lab with NAF and Biogen—breaking down the science of Friedreich Ataxia in a new video series. WATCH NOW
Written by Celeste Suart, PhD The end of October 2025 was a busy time for the research team here at NAF. We had delegates at two different research conferences: the Clinical Trials in Inherited Ataxias (CTAX) conference and the Amsterdam International Ataxia Patient Conference. Here are a few highlights from Read More…
Written by Taylor Stolberg Faces of Ataxia Research highlights scientists whose work is supported by grants from NAF. Each story shows how our donors are fueling discoveries that bring us closer to effective treatments and a cure for Ataxia. Meet the Researcher Project title: Early Career Investigator Award (2024): “Decoding Read More…
Written by Taylor Stolberg Faces of Ataxia Research highlights scientists whose work is supported by grants from NAF. Each story shows how our donors are fueling discoveries that bring us closer to effective treatments and a cure for Ataxia. Meet the Researcher Project title: Research Seed Money Grant (2025): “Uncovering Read More…
Biohaven announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) seeking approval of VYGLXIA (troriluzole) for the treatment of spinocerebellar ataxia (SCA). A CRL means the FDA has completed its review and determined that the Read More…
Written by Taylor Stolberg Faces of Ataxia Research highlights scientists whose work is supported by grants from NAF. Each story shows how our donors are fueling discoveries that bring us closer to effective treatments and a cure for Ataxia. Meet the Researcher Project title: Graduate Research Fellowship (2024): “Elucidating cholesterol Read More…
Drug companies must follow a detailed process to build and submit their New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). You can read more about NDAs in an earlier PrepRARE article here. But did you know that the FDA has its own set of rules to Read More…
If you’ve ever felt overwhelmed trying to understand complex medical research, you’re not alone. That’s why SCAsource was created—to make Ataxia research accessible to everyone. What is SCAsource? SCAsource is a publication where Ataxia researchers write plain-language articles about the latest research studies and scientific discoveries. It’s designed specifically for Read More…
We’re proud to announce that we funded 18 research grants for 2025 totaling $730K! For the funding term of March 1, 2025 – February 28, 2026, NAF received 96 Letters of Intent and 33 grant applications. ~50 scientific reviewers scored full applications, assigning a score between 1.0 and 5.0 (1= outstanding) Read More…
In clinical research, scientists design studies to learn more about diseases and answer questions about new treatment options. Interventional clinical trials are used to better understand the safety and effectiveness of a new drug or medical device. Observational clinical trials help researchers learn more about how diseases develop over time Read More…
NAF Awarded a Record Number of Projects in 2024 18 Studies Funded Totaling $845k Funded! We had our most competitive year ever for Ataxia research grant applications! As a result of the generosity of our donors, NAF was able to fund a record number of Ataxia research grants in 2024! Read More…
